TD Cowen Cuts Insmed (NASDAQ:INSM) Price Target to $241.00

Insmed (NASDAQ:INSM) had its price target trimmed by TD Cowen from $269.00 to $241.00 in a report published on Thursday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on INSM. Evercore ISI reiterated an “outperform” rating and issued a $180.00 price objective on shares of Insmed in a research note on Wednesday, October 1st. JPMorgan Chase & Co. raised their target price on Insmed from $111.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, August 20th. Leerink Partners reissued an “outperform” rating on shares of Insmed in a report on Thursday. Jefferies Financial Group set a $269.00 target price on Insmed in a research note on Wednesday, December 10th. Finally, Rothschild Redb upgraded shares of Insmed to a “strong-buy” rating in a research note on Thursday, December 4th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $205.41.

Insmed Trading Up 5.0%

NASDAQ:INSM opened at $174.84 on Thursday. The company’s 50 day moving average is $187.66 and its 200-day moving average is $143.51. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. Insmed has a 12 month low of $60.40 and a 12 month high of $212.75. The firm has a market cap of $37.29 billion, a price-to-earnings ratio of -28.25 and a beta of 1.01.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The firm had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The business’s quarterly revenue was up 52.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.27) earnings per share. Equities analysts anticipate that Insmed will post -4.56 EPS for the current year.

Insider Buying and Selling at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 30,000 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $194.00, for a total transaction of $5,820,000.00. Following the completion of the sale, the insider owned 36,461 shares in the company, valued at approximately $7,073,434. The trade was a 45.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Elizabeth M. Anderson sold 5,000 shares of the stock in a transaction on Monday, November 24th. The shares were sold at an average price of $204.58, for a total value of $1,022,900.00. Following the completion of the transaction, the director directly owned 58,729 shares in the company, valued at approximately $12,014,778.82. This trade represents a 7.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 157,829 shares of company stock valued at $30,266,463 over the last 90 days. Company insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Insmed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Chung Wu Investment Group LLC acquired a new position in shares of Insmed in the second quarter valued at approximately $173,000. Resolute Capital Asset Partners LLC bought a new stake in Insmed in the 2nd quarter valued at $2,748,000. Caxton Associates LLP bought a new stake in Insmed in the 1st quarter valued at $441,000. Assenagon Asset Management S.A. grew its holdings in Insmed by 84.5% in the 2nd quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company’s stock valued at $7,387,000 after buying an additional 33,626 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new position in Insmed during the 2nd quarter worth $5,578,000.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Unusual bullish options activity: traders bought a large block of INSM calls (≈6,582 contracts, +78% vs. average), signaling speculative or hedge interest that can support a bounce after the sell‑off.
• Positive Sentiment: Pipeline add — Insmed announced it is adding a new monoclonal‑antibody asset while reshaping its pipeline, which investors may view as a constructive move to offset the terminated sinus program. INSM Stock Plummets on Sinus Study Failure, Adds New Pipeline Asset
• Neutral Sentiment: Analysts trimmed targets but mostly stayed constructive — TD Cowen cut its target to $241 and Guggenheim trimmed to $221 while maintaining buy ratings; these lower targets temper upside but keep institutional support. Benzinga analyst note
• Negative Sentiment: Clinical failure and program termination: a Phase IIb trial in chronic rhinosinusitis showed no benefit, leading Insmed to discontinue development of the drug — the principal trigger for the multi‑day share plunge and elevated volatility. High‑flying Insmed stumbles with rhinosinusitis trial failure for Brinsupri
• Negative Sentiment: Market reaction and commentary: coverage noted a near‑20% drop after hours and broad analyst/media focus on the failure; sell‑side and floor commentary (Mizuho/Barron’s) emphasized the stock’s sharp decline. Insmed Stock Plummets 19%
• Negative Sentiment: Analyst EPS downgrade: HC Wainwright cut FY2028 EPS estimates (now $3.15 from $3.42), signaling reduced near‑term earnings expectations tied to program changes and greater uncertainty.
• Negative Sentiment: Insider sale: CEO William Lewis sold 10,699 shares at an average ~$167 on Dec. 18 (SEC filing), reducing his stake ~3.4% — insider selling often raises investor concern when timed near volatile news. SEC Form 4 — William Lewis sale

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.